Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Azurrx Biopharma Inc (AZRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
AzurRx BioPharma Receives $2 Million in Proceeds from Exercise of Warrants

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that it...

AZRX : 3.48 (-0.57%)
AzurRx BioPharma Announces Publication of U.S. Patent Application for AZX1101

AzurRx BioPharma Inc.(NASDAQ:AZRX) ("AzurRx" or the "Company"), today announced that the United States Patent and Trademark Office has published patent application number 15/519424, entitled "Hybrid Proteinaceous...

AZRX : 3.48 (-0.57%)
AzurRx BioPharma to Present at the 2017 LD Micro 10th Annual Main Event Conference (December 5th)

AzurRx BioPharma, Inc.(NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company...

AZRX : 3.48 (-0.57%)
AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission

AzurRx BioPharma Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), announced the submission of an Investigational Medicinal Product Dossier (IMPD) for its lead product MS1819-SD, a recombinant lipase for...

AZRX : 3.48 (-0.57%)
AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company") a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases today announced the appointment...

AZRX : 3.48 (-0.57%)
AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)

AzurRx BioPharma Inc.(NASDAQ:AZRX) ("AzurRx" or the "Company"), today provided an update on the first six treated patients in its ongoing Phase IIa trial of MS1819-SD, a recombinant lipase, for the treatment...

AZRX : 3.48 (-0.57%)
AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company") a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases today announced the appointment...

AZRX : 3.48 (-0.57%)
AzurRx BioPharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company...

AZRX : 3.48 (-0.57%)
AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis

Results on First Six Patients Expected in September

AZRX : 3.48 (-0.57%)
BUYINS.NET: AZRX SqueezeTrigger Price is $4.07. There is $93,257 That Short Sellers Still Need To Cover.

BUYINS.NET / www.buyins.net is monitoring AzurRX Biopharma (NASDAQ:AZRX) in real time and just received an alert that AZRX is crossing above its primary SqueezeTrigger Price, the price that a short squeeze...

AZRX : 3.48 (-0.57%)
AzurRx BioPharma Announces Closing of $5.0 Million Private Financing

AzurRx BioPharma, Inc.(NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the closing...

AZRX : 3.48 (-0.57%)
AzurRx BioPharma to Present at the 2017 LD Micro Invitational Conference (June 6) and the 2017 Marcum MicroCap Conference (June 15)

AzurRx BioPharma, Inc.(NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company...

AZRX : 3.48 (-0.57%)

Van Meerten Stock Picks

My 5 Favorite Mid Cap Stocks
This morning I wanted to find 5 Mid Cap stocks that had great returns over the past year and still seem to have some juice left.
KBH -1.63 , IPGP +2.02 , FSLR -2.19 , NVR -17.23 , SGMS +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.39%) are up +0.41% at a fresh record nearest-futures high as growth optimism fuels gains in global equity markets. Gains in technology stocks are leading the overall market higher as... Read More

Chart of the Day

Chart of the Day

Audentes Therapeutcs (BOLD) is rhe Barchart Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 174.58+ and gained 111.74% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures bounced back from Friday’s bearish USDA reports to close Tuesday with gains of 2 cents in most nearby contracts. The weekly Export Inspections report indicated just 584,389 MT of corn was shipped during the week of Jan 11. That is ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.